Dexcom bet on the high financial ceiling that exists by integrating its glucose monitoring capabilities into the ring, culminating in a $75m investment in Ō ...

Continuous glucose monitors like Dexcom's Stelo and Abbott's Lingo are small, wearable devices that track blood glucose ...

Medical device specialist DexCom (NASDAQ: DXCM) has substantially underperformed the market over the trailing-12-month period ...

The bull market of the past year or more has reinvigorated investors' interest across a range of industries, and the ...

The medical device company has seen its growth rate take a hit in recent quarters. DexCom blames its restructuring, but rising demand for GLP-1 drugs could be an issue. The stock's valuation has ...

American Diversified Holdings Corporation (OTC Pink: ADHC) pleased to provide the shareholder community an update on the ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly ...

Dexcom (DXCM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 13. Analyst Mike Kratky from Leerink Partners maintained a Buy rating on the ...

including Dexcom’s glucose biosensors and apps, as well as the Oura Ring and accompanying app. The first app integration is expected to roll out in the first half of 2025. Importantly ...